FDA OKs ZymoGenetics' Recothrom

01/17/2008 | Boston Globe (tiered subscription model), The

ZymoGenetics announced Thursday that the FDA has approved Recothrom Thrombin, its surgical anti-clotting product. In a late-stage trial, the drug proved as effective as bovine thrombin, a currently available product, the company said. Under terms of a global agreement, Bayer HealthCare Pharmaceuticals will back the U.S. launch of Recothrom for three years.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Medtronic
Fridley, MN
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC